Cladis Investment Advisory LLC Purchases 5,036 Shares of Pfizer Inc. (NYSE:PFE)

Cladis Investment Advisory LLC increased its stake in Pfizer Inc. (NYSE:PFE) by 8.7% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 63,174 shares of the biopharmaceutical company’s stock after purchasing an additional 5,036 shares during the quarter. Pfizer comprises about 1.2% of Cladis Investment Advisory LLC’s holdings, making the stock its 23rd largest position. Cladis Investment Advisory LLC’s holdings in Pfizer were worth $1,676,000 as of its most recent filing with the SEC.

Other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in Pfizer by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 518,535,151 shares of the biopharmaceutical company’s stock valued at $13,756,738,000 after buying an additional 2,285,276 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Pfizer by 19.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock worth $4,124,330,000 after buying an additional 25,315,159 shares during the period. Geode Capital Management LLC lifted its stake in shares of Pfizer by 2.5% during the 4th quarter. Geode Capital Management LLC now owns 120,589,782 shares of the biopharmaceutical company’s stock valued at $3,190,131,000 after buying an additional 2,923,537 shares in the last quarter. Norges Bank purchased a new stake in Pfizer during the 4th quarter valued at approximately $2,328,986,000. Finally, Massachusetts Financial Services Co. MA lifted its position in shares of Pfizer by 7.5% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company’s stock worth $2,029,604,000 after buying an additional 5,350,381 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on PFE. UBS Group boosted their target price on Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research report on Wednesday, April 30th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Cantor Fitzgerald began coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price objective for the company. Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Finally, Citigroup reiterated a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. One analyst has rated the stock with a sell rating, eight have given a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.17.

Insider Transactions at Pfizer

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the firm’s stock in a transaction dated Thursday, February 13th. The shares were bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.06% of the stock is currently owned by corporate insiders.

Pfizer Stock Performance

Shares of NYSE PFE opened at $22.78 on Thursday. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The company has a market cap of $129.18 billion, a PE ratio of 16.15, a P/E/G ratio of 0.64 and a beta of 0.58. The stock has a 50 day simple moving average of $24.15 and a 200-day simple moving average of $25.65. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same period in the previous year, the firm earned $0.82 earnings per share. Pfizer’s revenue for the quarter was down 7.8% compared to the same quarter last year. On average, equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 annualized dividend and a yield of 7.55%. Pfizer’s dividend payout ratio (DPR) is currently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.